Lampire Biological Labs Inc.

Lampire Biological Labs Inc., a for-profit manufacturer of animal-derived biological products, supplies fresh and processed blood cells, serum, and tissue materials to federal research, diagnostic, and public health agencies as a prime contractor across specialized procurement vehicles and purchase orders. The vendor operates full-and-open (no set-aside designations across the cited recent awards, with one small-business set-aside on a 2025 USDA Agricultural Research Service purchase order), and competes predominantly on direct government procurement channels rather than on government-wide vehicles.

Lampire Biological Labs is headquartered in Ottsville, Pennsylvania, with place of performance at a facility in Pipersville, Bedminster Township, Pennsylvania. The vendor classifies primarily under NAICS 325414 (Biological Product Manufacturing except Diagnostic), with secondary codes reflecting turkey and rabbit production and in-vitro diagnostic substance manufacturing. The company manufactures and distributes fresh blood products — including defibrinated sheep, rabbit, horse, turkey, chicken, and guinea pig red blood cells — and related biologicals to support federal blood compatibility testing, diagnostic assay development, and research operations.

Federal customer concentration splits across two tiers. By award count, the top five customers account for 53% of recent awards: the Department of Agriculture's Food Safety and Inspection Service (11 awards, $243 thousand combined potential value), the Centers for Disease Control and Prevention Pittsburgh (11 awards, $4.4 million), the Department of the Army Medical Command (9 awards, $132 thousand), the National Institute of Allergy and Infectious Diseases (6 awards, $33 thousand), and the USDA Agricultural Research Service Plains Area (4 awards, $38 thousand). By potential value, however, the distribution is heavily weighted to a single vehicle: the National Institutes of Health's Office of Logistics and Acquisition Operations Blanket Purchase Agreement, which carries a $50 million ceiling (3 awards, representing 99% of the vendor's combined potential value across the 78 recent awards). The CDC and USDA customer relationships, while lower in dollars, represent the vendor's sustained operational base.

Lampire Biological Labs holds a $50 million single-award BPA with NIH (awarded April 30, 2024, ceiling through April 30, 2026) covering tissue, cell culture media, animal serum, biologicals, and blood products for research and diagnostic applications. Task orders under legacy indefinite delivery contracts with USDA (AG3A94C120019, 7 task orders, $17 thousand combined potential value) and HHS (HHSN263199900050334B, 5 task orders, $68 thousand) supplement the NIH vehicle. Recent named prime awards include a $1.537 million definitive contract from CDC Pittsburgh (September 22, 2026) for fresh turkey, chicken, guinea pig, and horse red blood cells under Executive Order 14398, a $189,290 FDA purchase order (September 30, 2026) for animal whole blood for blood compatibility testing, a $25,740 USDA Agricultural Research Service purchase order (April 1, 2025) for weekly defibrinated sheep blood shipments to Manhattan, Kansas (base plus four optional one-year periods through March 31, 2030), and a $70,080 Defense Health Agency purchase order (April 1, 2022) for defibrinated rabbit blood in 50-milliliter units (ultimate completion March 31, 2027).

Award activity over the past five years is sparse — one award per year 2022 through 2025, with two in 2026 — across 78 total recent prime awards. The vendor carries no subcontract footprint (0% of awards). Recompete exposure in the next twenty-four months is minimal: one award (combined potential value $70 thousand) faces ultimate completion inside that window. The $50 million NIH BPA, however, reaches final expiration April 30, 2026, creating a recompete or renewal decision point within the same period.